How Martin Shkreli Used Social Media To Fuel His Short-Selling Shenanigans

July 20, 2017

Over the last several months, someone using the pseudonym “Art Doyle” released online reports — I use the word “reports” loosely — to attack several biotech stocks.

Continue Reading

Why The Street Should Fear The Senate Healthcare Bill

June 22, 2017

As the Republican Senate majority unveiled its draft healthcare bill Thursday, there was a rally in healthcare stocks in anticipation of reduced government regulation.

Continue Reading

WBB Securities Acts as Co-Manager in $40 Million Follow-on Financing for Corium International, Inc.

May 31, 2017

WBB Securities acted as co-manager to a transaction for Corium International, Inc., a commercial stage developer of transdermal healthcare products.

Continue Reading

Why Healthcare Reform Won’t Be Rushed — And It Isn’t Political

April 1, 2017

Republicans learned that they must tread carefully in their plans to replace the ACA as the consequences of their actions will result in significant disruption across the healthcare industry.

Continue Reading

WBB Securities Acts as Financial Advisor to T2 Biosystems for $50 Million Credit Facility

January 5, 2017

WBB Securities acted as financial advisor to T2 Biosystems, Inc., a manufacturer of next generation diagnostic equipment, for a credit facility up to $50 million.

Continue Reading

Trump, Interest Rates, And Biotech Investing In 2017

December 23, 2016

We are heading into 2017 with a great deal of uncertainty, but if President-elect Trump governs the nation as he said he would – unconventionally and unpredictably – we may experience a significant uptick in market volatility as foreign governments and global markets react to America’s new stance in the world.

Continue Reading

Siemens And Northwell Announce Alliance, Enter Big Data Arms Race

December 1, 2016

In an era where a doctor’s office can generate a terabyte of data easily and toasters can speak to refrigerators, we are in an unprecedented age of information and connectivity.

Continue Reading

After Lilly Bombs, Could Alzheimer’s Become Healthcare’s Trumpshot?

November 30, 2016

If the healthcare industry’s approach to Alzheimer’s disease were a building project, it could best be described as constructing a skyscraper from the top down–possible, yet at best impractical.

Continue Reading

5 Healthcare Questions That Should (But Won’t) Be Asked At The Debate

October 7, 2016

As the election draws closer, issue polls consistently rank health care affordability at or near the top of American voters’ concerns.

Continue Reading

WBB Securities Acts as Co-Manager for $300 Million Public Offering for Sarepta Therapeutics

September 29, 2016

WBB Securities acted as co-manager to a transaction for Sarepta Therapeutics, Inc., a developer of innovative RNA-targeted therapeutics.

Continue Reading